ESC Congress - European Society of Cardiology Congress

Host Craig Beavers discusses the validity of meta-analyses and highlights analyses from European Society of Cardiology (ESC) 2025 with Bill Baker, PharmD, FCCP, FACC, FAHA.

A multicenter registry analysis reveals that high-risk cardiovascular patients often miss opportunities to receive pneumococcal and influenza vaccinations, showcasing gaps that could be filled by pharmacists.

Participating in a pharmacist-led secondary intervention clinic helped achieve large reductions in cholesterol levels among patients who have experienced an acute coronary syndrome.

Investigators emphasize that early cardiovascular risk assessments and preventive strategies are necessary for women with polycystic ovarian syndrome (PCOS).

The 2 abstracts, which were presented at the European Society of Cardiology 2025 Congress, utilized data from the CDC WONDER database.

In combination with lipid-lowering therapy, inclisiran allowed patients with hypercholesterolemia to reach their low-density lipoprotein cholesterol (LDL-C) goals without associated muscle-related adverse events.

Host Craig Beavers sits down with Lorenz van der Linden, a Belgian pharmacist, to dive deep into 2 groundbreaking trials from the European Society of Cardiology (ESC) 2025 Congress.

The trial results, which showed baxdrostat significantly reduced mean seated systolic blood pressure in uncontrolled hypertension, were presented at the 2025 European Society of Cardiology Congress.

Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.

Host Craig Beavers reviews key studies and insights from the upcoming ESC Congress 2025, focusing on groundbreaking research in cardiology and treatment advancements.

Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.

There are several roles pharmacists can play in managing patients with cardiovascular disease, including blood pressure and medication monitoring.

The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care.

John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology, discusses the vexing problem of patients who fail to fill or take recommended medications.

John Rumsfeld, MD, PhD, chief innovation officer at the American College of Cardiology, discusses the digital innovations that will have major effects on the cardiovascular field in years to come.

In this clip, Deepak Bhatt, MD, discusses how pharmacists should counsel patients taking aspirin and rivaroxaban, if approved.

In this clip, Deepak Bhatt, MD, discusses the results of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, presented at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

In this clip, Steven Nissen, MD, of the Cleveland Clinic discusses some new data on anti-inflammatories and cardiovascular events that were presented this week at the European Society of Cardiology.